Determining the clinical significance of monoclonal gammopathy of undetermined significance: A SEER-medicare population analysis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 3, 2015, Pages 177-186.e4

  Go, Ronald S ^a,d   Gundrum, Jacob D ^b   Neuner, Joan M ^c  

^a Gundersen Health System   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Complications; Lymphoplasmacytic lymphoma; Multiple myeloma; Outcomes; Waldenstr m macroglobulinemia

Indexed keywords

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL FEATURE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PROPENSITY SCORE; SPINAL CORD COMPRESSION; VERY ELDERLY; WALDENSTROEM MACROGLOBULINEMIA; CANCER REGISTRY; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; DISEASE COURSE; HEALTH SURVEY; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MORTALITY; NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; SOCIOECONOMICS; SURVIVAL; UNITED STATES;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; NEOPLASMS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84923340946     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.09.004     Document Type: Article

References (25)

1. R.A. Kyle, T.M. Therneau, and S.V. Rajkumar Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med 354 2006 1362 1369
2. O. Landgren, and B.M. Weiss Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis Leukemia 23 2009 1691 1697
3. R.S. Go, and L.M. Doyle A monoclonal gammopathy in search of clinical significance: 57 years later Blood 114 2009 2355 2356 author reply 2356-7
4. R.A. Kyle, T.M. Therneau, and S.V. Rajkumar A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 2002 564 569
5. S.V. Rajkumar, R.A. Kyle, and T.M. Therneau Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance Blood 106 2005 812 817
6. R.A. Kyle, and S.V. Rajkumar Monoclonal gammopathy of undetermined significance Br J Haematol 134 2006 573 589
7. O. Landgren, R.A. Kyle, and R.M. Pfeiffer Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 2009 5412 5417
8. R.A. Kyle, B.G. Durie, and S.V. Rajkumar Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Leukemia 24 2010 1121 1127
9. SEER-Medicare Linked Database. National Cancer Institute Web site. Available at: http://healthservices.cancer.gov/seermedicare/. Accessed May 15, 2014.
10. Area Health Resource File (AHRF) 2012-2013 US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions Rockville, MD
11. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
12. M. Pineda-Roman, V. Bolejack, and V. Arzoumanian Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease Br J Haematol 136 2007 393 399
13. H. Gregersen, H.T. Sorensen, M.C. Engebjerg, P. Jensen, M.T. Severinsen, and M. Norgaard Survival of cancer patients with prior monoclonal gammopathy of undetermined significance Eur J Intern Med 21 2010 564 568
14. Chronic Conditions Data Warehouse (CCW). Available at: https://www.ccwdata.org/web/guest/home. Updated 2013. Accessed May 15, 2014.
15. G. Bianchi, R.A. Kyle, and C.L. Colby Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications Blood 116 2010 2019 2025
16. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
17. R. Cook Economic and clinical impact of multiple myeloma to managed care J Manag Care Pharm 14 7 suppl 2008 19 25
18. R.A. Kyle, M.A. Gertz, and T.E. Witzig Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33
19. H. Kaufmann, J. Ackermann, and V. Odelga Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS Eur J Clin Invest 38 2008 53 60
20. F. Patriarca, R. Fanin, and F. Silvestri Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammopathy of undetermined significance Leuk Lymphoma 34 1999 591 596
21. S.K. Kumar, D. Dingli, and M.Q. Lacy Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders Br J Haematol 141 2008 205 211
22. J.A. Katzmann, R. Clark, and R.A. Kyle Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS Leukemia 27 2013 208 212
23. S.V. Rajkumar Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma Am J Hematol 87 2012 453 454
24. Surveillance, Epidemiology, and End Results Program. National Cancer Institute. Available at: http://seer.cancer.gov/. Accessed August 27, 2014.
25. M. Al-Hamadani, S.K. Hashmi, and R.S. Go Use of autologous stem cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents Am J Hematol 89 2014 825 830